New Drug Rusfertide Shows Promise In Deadly Blood Cancer Control | Rusfertide For Polycythemia vera

Cancer is one of the largest health problems in the world. According to Our World In Data, Every year cancer kills about ten million people. After cardiovascular diseases cancer is the second leading cause of death around the World. Cancer contributes to the cause of every sixth death. Polycythemia vera is a type of blood cancer in which the bone marrow of patients produces too many red blood cells.

 According to targeted oncology, the overall survival rate of patients with Polycythemia vera is 20 years. The good news is that there is a groundbreaking discovery regarding polycythemia vera. A new drug called Rusfertide has shown guaranteed results in a clinical trial for Polycythemia vera.

Polycythemia vera is a rare type of blood cancer that is a life-threatening disease. The new drug Rusfertide decreased the excess production of RBCs in the clinical trial. The clinical trial was led by researchers from the Icahn School of Medicine and involved 70 patients. 

These 70 patients chosen for clinical trial were dependent on phlebotomy. In the phlebotomy procedure, blood is removed from the body to reduce the blood volume. After injecting the new drug Rusfertide for four months, patients were monitored for symptoms and blood counts.

After four months, the results were published in The New England Journal of Medicine, Clinical trial results showed that the new drug Rusfertide effectively reduced the need for phlebotomy. This drug also reduced the patient's quality of life suffering from Polycythemia vera. The safety profile of the drug was also favorable and was well tolerated by most patients. 

In Polycythemia vera, the bone marrow of patients produces too many RBCs. Excess production of RBCs can make the blood sticky and thick. This can increase the risk of clots, stroke, heart attack and other complicated problems.

The new drug Rusfertide works by binding to a protein called hepcidin. The protein hepcidin regulates iron in the body. By increasing hepcidin levels the new drug Rusfertide reduces the iron availability for RBC production. Thus, decreasing the RBC count and reducing the symptoms of polycythemia vera.

FAQ About Polycythemia vera, Cancer Drug and Rusfertide.

(1) Polycythemia Vera Survival Rate

 According to targeted oncology, the overall survival rate of patients with Polycythemia vera is 20 years.

(2) Polycythemia Vera Erythropoietin Level.

Polycythemia vera is a condition where your body makes too many RBCs. Erythropoietin level means the amount of a hormone called erythropoietin in your blood. In polycythemia vera, this level is usually low. This level remains low because your body doesn't need to make more red blood cells – it's already making too many. So, to put it simply, in polycythemia vera, the erythropoietin level is often low.

Note: We are not doctors. The information here is for general purposes only. It's not a substitute for professional medical advice. Always consult a healthcare provider before starting any treatment or making changes to your health regimen. We're not responsible for any actions taken based on the information provided.